The Efficacy of 18F-FDG PET/CT and Superparamagnetic Nanoferric Oxide MRI in the Diagnosis of Lung Cancer and the Value of 18F-FDG PET/CT in the Prediction of Lymph Node Metastasis

Abstract

In China, lung cancer is one of the leading causes of death among residents. Early diagnosis is of great significance for early interventional treatment and prolonging survival. PET/CT uses positron radiopharmaceuticals to observe the physiological and biochemical changes of the drug and its metabolites in the body and finally diagnoses the disease. 18F-FDG is a commonly used imaging agent, but its short isotopic half-life limits clinical high-throughput testing. This study retrospectively analyzed the imaging material of 100 lung cancer patients pathologically confirmed. Patients with lymph node metastasis were classified into the LM group ( n = 30 cases), and those with no lymph node metastasis were classified into the NLM group ( n = 70 cases). The results showed that MRI of superparamagnetic nanoferric oxide was better than diagnosis of lung cancer by the 18F-FDG PET/CT and had a high predictive power for lymph node metastasis. These turned out to be high-value lung cancer diagnosis of superparamagnetic nanoferric oxide MRI and high-capacity lymph node metastasis prediction of 18F-FDG PET/CT, which were worthy of implementation.

Auxiliary Diagnosis of Lung Cancer with Magnetic Resonance Imaging Data under Deep Learning

“…Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can extract a variety of quantitative parameters from the time-intensity curve [ 10 ]. These parameters have been proven in numerous clinical studies to be surrogate indicators of tumor diffusion, blood flow, microvessel density, and capillary permeability [ 11 ]. Semiquantitative DCE-MRI parameters, like time to peak, maximum enhancement ratio, A, B, C, and D time-intensity signal curves, and pharmacokinetic parameters, have shown the potential to differentiate lung lesions [ 12 ].…”